Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden

详细信息    查看全文

• 作者：Paul Dowling ; Michael Henry ; Paula Meleady ; Colin Clarke ; Kathy Gately…
• 关键词：Breast cancer ; Biomarkers ; Mass spectrometry ; Cancer antigen 15 ; 3 (CA15 ; 3) ; 12 ; Hydroxyeicosatetraenoic acid (12 ; HETE) ; Glutamate
• 刊名：Metabolomics
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：11
• 期：3
• 页码：620-635
• 全文大小：563 KB
• 参考文献：Asiago, V. M., Alvarado, L. Z., Shanaiah, N., Gowda, G. A., Owusu-Sarfo, K., Ballas, R. A., et al. (2010). Early detection of recurrent breast cancer using metabolite profiling. Cancer Research, 70(21), 8309鈥?318. doi:10.鈥?158/鈥?008-5472.鈥婥AN-10-1319 .View Article PubMed Central PubMed
  Benson, J. R., & Jatoi, I. (2012). The global breast cancer burden. Future Oncology, 8(6), 697鈥?02. doi:10.鈥?217/鈥媐on.鈥?2.鈥?1 .View Article PubMed
  Bhattacharya, P., & Maity, P. (2000). Localization of phosphate dependent glutaminase in ascites fluid of ovarian cancer patient. Pathology and Oncology Research, 6(3), 217鈥?23.View Article PubMed
  Bigbee, W. L., Gopalakrishnan, V., Weissfeld, J. L., Wilson, D. O., Dacic, S., Lokshin, A. E., et al. (2012). A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. Journal of Thoracic Oncology, 7(4), 698鈥?08. doi:10.鈥?097/鈥婮TO.鈥?b013e31824ab6b0鈥?/span> .View Article PubMed Central PubMed
  Bostr枚m, P., S枚derstr枚m, M., Vahlberg, T., S枚derstr枚m, K. O., Roberts, P. J., Carp茅n, O., et al. (2011). MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer, 11, 348. doi:10.鈥?186/鈥?471-2407-11-348 .View Article PubMed Central PubMed
  Brayman, M., Thathiah, A., & Carson, D. D. (2004). MUC1: A multifunctional cell surface component of reproductive tissue epithelia. Reproductive Biology and Endocrinology, 2, 4. doi:10.鈥?186/鈥?477-7827-2-4 .View Article PubMed Central PubMed
  Dowling, P., Clarke, C., Hennessy, K., Torralbo-Lopez, B., Ballot, J., Crown, J., et al. (2012). Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. International Journal of Cancer, 131(4), 911鈥?23. doi:10.鈥?002/鈥媔jc.鈥?6462 .View Article
  Drukteinis, J. S., Mooney, B. P., Flowers, C. I., & Gatenby, R. A. (2013). Beyond mammography: New frontiers in breast cancer screening. American Journal of Medicine, 126(6), 472鈥?79. doi:10.鈥?016/鈥媕.鈥媋mjmed.鈥?012.鈥?1.鈥?25 .View Article PubMed Central PubMed
  Duffy, M. J. (2006). Serum tumor markers in breast cancer: Are they of clinical value? Clinical Chemistry, 52(3), 345鈥?51. doi:10.鈥?373/鈥媍linchem.鈥?005.鈥?59832 .View Article PubMed
  Duffy, M. J. (2013). Tumor markers in clinical practice: A review focusing on common solid cancers. Medical Principles and Practice, 22(1), 4鈥?1. doi:10.鈥?159/鈥?00338393 .View Article PubMed
  Duffy, M. J., Evoy, D., & McDermott, E. W. (2010). CA 15-3: Uses and limitation as a biomarker for breast cancer. Clinica Chimica Acta, 411(23鈥?4), 1869鈥?874. doi:10.鈥?016/鈥媕.鈥媍ca.鈥?010.鈥?8.鈥?39 .View Article
  Erickson, J. W., & Cerione, R. A. (2010). Glutaminase: A hot spot for regulation of cancer cell metabolism? Oncotarget, 1(8), 734鈥?40.PubMed Central PubMed
  F眉rstenberger, G., Krieg, P., M眉ller-Decker, K., & Habenicht, A. J. (2006). What are cyclooxygenases and lipoxygenases doing in the driver鈥檚 seat of carcinogenesis? International Journal of Cancer, 119(10), 2247鈥?254. doi:10.鈥?002/鈥媔jc.鈥?2153 .View Article
  Graham, L. J., Shupe, M. P., Schneble, E. J., Flynt, F. L., Clemenshaw, M. N., Kirkpatrick, A. D., et al. (2014). Current approaches and challenges in monitoring treatment responses in breast cancer. Journal of Cancer, 5(1), 58鈥?8. doi:10.鈥?150/鈥媕ca.鈥?047 .View Article PubMed Central PubMed
  Haagensen, D. E., Kister, S. J., Vandevoorde, J. P., Gates, J. B., Smart, E. K., Hansen, H. J., et al. (1978). Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer, 42(3 Suppl), 1512鈥?519.View Article PubMed
  Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25(33), 5287鈥?312. doi:10.鈥?200/鈥婮CO.鈥?007.鈥?4.鈥?364 .View Article PubMed
  Hayes, D. F., Sekine, H., Ohno, T., Abe, M., Keefe, K., & Kufe, D. W. (1985). Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. Journal of Clinical Investigation, 75(5), 1671鈥?678. doi:10.鈥?172/鈥婮CI111875 .View Article PubMed Central PubMed
  Jiang, W. G., Douglas-Jones, A., & Mansel, R. E. (2003). Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukotrienes and Essential Fatty Acids, 69(4), 275鈥?81.View Article
  Katt, W. P., Ramachandran, S., Erickson, J. W., & Cerione, R. A. (2012). Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Molecular Cancer Therapeutics, 11(6), 1269鈥?278. doi:10.鈥?158/鈥?535-7163.鈥婱CT-11-0942 .View Article PubMed Central PubMed
  Klee, E. W., Bondar, O. P., Goodmanson, M. K., Dyer, R. B., Erdogan, S., Bergstralh, E. J., et al. (2012). Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clinical Chemistry, 58(3), 599鈥?09. doi:10.鈥?373/鈥媍linchem.鈥?011.鈥?71637 .View Article PubMed Central PubMed
  Koochekpour, S., Majumdar, S., Azabdaftari, G., Attwood, K., Scioneaux, R., Subramani, D., et al. (2012). Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clinical Cancer Research, 18(21), 5888鈥?901. doi:10.鈥?158/鈥?078-0432.鈥婥CR-12-1308 .View Article PubMed Central PubMed
  Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011). Otto Warburg鈥檚 contributions to current concepts of cancer metabolism. Nature Reviews Cancer, 11(5), 325鈥?37. doi:10.鈥?038/鈥媙rc3038 .View Article PubMed
  Kurebayashi, J., Nishimura, R., Tanaka, K., Kohno, N., Kurosumi, M., Moriya, T., et al. (2004). Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: A prospective study. Breast Cancer, 11(4), 389鈥?95.View Article PubMed
  艁awicki, S., B臋dkowska, G. E., & Szmitkowski, M. (2013). VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: A multivariate analysis with ROC curve. Growth Factors, 31(3), 98鈥?05. doi:10.鈥?109/鈥?8977194.鈥?013.鈥?97900 .View Article PubMed
  Liu, B., Maher, R. J., Hannun, Y. A., Porter, A. T., & Honn, K. V. (1994). 12(S)-HETE enhancement of prostate tumor cell invasion: Selective role of PKC alpha. Journal of the National Cancer Institute, 86(15), 1145鈥?151.View Article PubMed
  Lokich, J. J., Zamcheck, N., & Lowenstein, M. W. (1978). Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer: A predictor and monitor of response and relapse. Annals of Internal Medicine, 89(6), 902鈥?06.View Article PubMed
  Meleady, P., Gallagher, M., Clarke, C., Henry, M., Sanchez, N., Barron, N., et al. (2012a). Impact of miR-7 over-expression on the proteome of Chinese hamster ovary cells. Journal of Biotechnology, 160(3鈥?), 251鈥?62. doi:10.鈥?016/鈥媕.鈥媕biotec.鈥?012.鈥?3.鈥?02 .View Article PubMed
  Meleady, P., Hoffrogge, R., Henry, M., Rupp, O., Bort, J. H., Clarke, C., et al. (2012b). Utilization and evaluation of CHO-specific sequence databases for mass spectrometry based proteomics. Biotechnology and Bioengineering, 109(6), 1386鈥?394. doi:10.鈥?002/鈥媌it.鈥?4476 .View Article PubMed
  Milan, E., Lazzari, C., Anand, S., Floriani, I., Torri, V., Sorlini, C., et al. (2012). SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. Journal of Proteomics, 76 91鈥?01, doi:10.鈥?016/鈥媕.鈥媕prot.鈥?012.鈥?6.鈥?22 .
  Mirabelli, P., & Incoronato, M. (2013). Usefulness of traditional serum biomarkers for management of breast cancer patients. BioMed Research International, 2013, 685641. doi:10.鈥?155/鈥?013/鈥?85641 .View Article PubMed Central PubMed
  Molina, R., Aug茅, J. M., Escudero, J. M., Filella, X., Zanon, G., Pahisa, J., et al. (2010a). Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: Prognostic value. Tumour Biology, 31(3), 171鈥?80. doi:10.鈥?007/鈥媠13277-010-0025-9 .View Article PubMed
  Molina, R., Auge, J. M., Farrus, B., Zan贸n, G., Pahisa, J., Mu帽oz, M., et al. (2010b). Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clinical Chemistry, 56(7), 1148鈥?157. doi:10.鈥?373/鈥媍linchem.鈥?009.鈥?35566 .View Article PubMed
  Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., et al. (2005). Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biology, 26(6), 281鈥?93. doi:10.鈥?159/鈥?00089260 .View Article PubMed
  Monari, E., Casali, C., Cuoghi, A., Nesci, J., Bellei, E., Bergamini, S., et al. (2011). Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers. Proteome Science, 9(1), 55. doi:10.鈥?186/鈥?477-5956-9-55 .View Article PubMed Central PubMed
  Moreno-Aspitia, A., Hillman, D. W., Dyar, S. H., Tenner, K. S., Gralow, J., Kaufman, P. A., et al. (2013). Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer, 119(15), 2675鈥?682. doi:10.鈥?002/鈥媍ncr.鈥?8130 .View Article PubMed Central PubMed
  Mughal, A. W., Hortobagyi, G. N., Fritsche, H. A., Buzdar, A. U., Yap, H. Y., & Blumenschein, G. R. (1983). Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA, 249(14), 1881鈥?886.View Article PubMed
  Nakata, B., Ogawa, Y., Ishikawa, T., Ikeda, K., Kato, Y., Nishino, H., et al. (2000). Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer, 89(6), 1285鈥?290.View Article PubMed
  Namkoong, J., Shin, S. S., Lee, H. J., Mar铆n, Y. E., Wall, B. A., Goydos, J. S., et al. (2007). Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Research, 67(5), 2298鈥?305. doi:10.鈥?158/鈥?008-5472.鈥婥AN-06-3665 .View Article PubMed
  Park, B. J., Cha, M. K., & Kim, I. H. (2014). Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses. BMC Research Notes, 7(1), 7. doi:10.鈥?186/鈥?756-0500-7-7 .View Article PubMed Central PubMed
  Ripka, S., Riedel, J., Neesse, A., Griesmann, H., Buchholz, M., Ellenrieder, V., et al. (2010). Glutamate receptor GRIA3-target of CUX1 and mediator of tumor progression in pancreatic cancer. Neoplasia, 12(8), 659鈥?67.View Article PubMed Central PubMed
  Senkus, E., Cardoso, F., & Pagani, O. (2014). Time for more optimism in metastatic breast cancer? Cancer Treatment Reviews, 40(2), 220鈥?28. doi:10.鈥?016/鈥媕.鈥媍trv.鈥?013.鈥?9.鈥?15 .View Article PubMed
  Seregni, E., Coli, A., Mazzucca, N., & Italian Group RIA-IRMA Test, I. a. A. o. N. M. (2004). Circulating tumour markers in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 31(Suppl 1), S15鈥揝22. doi:10.鈥?007/鈥媠00259-004-1523-z .View Article PubMed
  Singh, A. K., Kant, S., Parshad, R., Banerjee, N., & Dey, S. (2011). Evaluation of human LOX-12 as a serum marker for breast cancer. Biochemical and Biophysical Research Communications, 414(2), 304鈥?08. doi:10.鈥?016/鈥媕.鈥媌brc.鈥?011.鈥?9.鈥?44 .View Article PubMed
  Soerjomataram, I., Lortet-Tieulent, J., Parkin, D. M., Ferlay, J., Mathers, C., Forman, D., et al. (2012). Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. Lancet, 380(9856), 1840鈥?850. doi:10.鈥?016/鈥婼0140-6736(12)60919-2 .View Article PubMed
  Speyer, C. L., Smith, J. S., Banda, M., DeVries, J. A., Mekani, T., & Gorski, D. H. (2012). Metabotropic glutamate receptor-1: A potential therapeutic target for the treatment of breast cancer. Breast Cancer Research and Treatment, 132(2), 565鈥?73. doi:10.鈥?007/鈥媠10549-011-1624-x .View Article PubMed Central PubMed
  Tondini, C., Hayes, D. F., Gelman, R., Henderson, I. C., & Kufe, D. W. (1988). Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Research, 48(14), 4107鈥?112.PubMed
  Vonach, C., Viola, K., Giessrigl, B., Huttary, N., Raab, I., Kalt, R., et al. (2011). NF-魏B mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. British Journal of Cancer, 105(2), 263鈥?71. doi:10.鈥?038/鈥媌jc.鈥?011.鈥?94 .View Article PubMed Central PubMed
  Zhao, Y., Butler, E. B., & Tan, M. (2013). Targeting cellular metabolism to improve cancer therapeutics. Cell Death and Disease, 4, e532. doi:10.鈥?038/鈥媍ddis.鈥?013.鈥?0 .View Article PubMed Central PubMed
  
• 作者单位：Paul Dowling (1) (2)
  Michael Henry (2)
  Paula Meleady (2)
  Colin Clarke (2)
  Kathy Gately (3)
  Kenneth O鈥橞yrne (3)
  Elizabeth Connolly (4)
  Vincent Lynch (2)
  Jo Ballot (5)
  Giuseppe Gullo (5)
  John Crown (5)
  Michael Moriarty (2)
  Martin Clynes (2)
  
  1. Department of Biology, The National University of Ireland Maynooth, Maynooth, Kildare, Ireland
  2. National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
  3. Institute of Molecular Medicine, Trinity Centre for Health Sciences, Trinity College Dublin, St. James鈥?Hospital, Dublin, Ireland
  4. Department of Surgery, St. James鈥檚 Hospital, Dublin, Ireland
  5. Molecular Therapeutics for Cancer Ireland (MTCI), St. Vincent鈥檚 University Hospital, Dublin, Ireland
  
• 刊物主题：Biochemistry, general; Molecular Medicine; Cell Biology; Developmental Biology; Biomedicine general;
• 出版者：Springer US
• ISSN：1573-3890

文摘

Evaluation of protein and metabolite expression patterns in blood using mass spectrometry and high-throughput antibody-based screening platforms has potential for the discovery of new biomarkers for managing breast cancer patient treatment. Previously identified blood-based breast cancer biomarkers, including cancer antigen 15.3 (CA15-3) are useful in combination with imaging (computed tomography scans, magnetic resonance imaging, X-rays) and physical examination for monitoring tumour burden in advanced breast cancer patients. However, these biomarkers suffer from insufficient levels of accuracy and with new therapies available for the treatment of breast cancer, there is an urgent need for reliable, non-invasive biomarkers that measure tumour burden with high sensitivity and specificity so as to provide early warning of the need to switch to an alternative treatment. The aim of this study was to identify a biomarker signature of tumour burden using cancer and non-cancer (healthy controls/non-malignant breast disease) patient samples. Results demonstrate that combinations of three candidate biomarkers from Glutamate, 12-Hydroxyeicosatetraenoic acid, Beta-hydroxybutyrate, Factor V and Matrix metalloproteinase-1 with CA15-3, an established biomarker for breast cancer, were found to mirror tumour burden, with AUC values ranging from 0.71 to 0.98 when comparing non-malignant breast disease to the different stages of breast cancer. Further validation of these biomarker panels could potentially facilitate the management of breast cancer patients, especially to assess changes in tumour burden in combination with imaging and physical examination.